BIOLASE Technology, Inc.

Federico Pignatelli

Chairman, CEO & President

NASDAQ: BLTI

www.biolase.com

Orlando

|

February 9 –

12, 2012 •

Gaylord Palms Hotel & Convention Center

Exhibit 99.1

Safe Harbor Statement

This presentation may contain forward-looking statements that are based on our current expectations, estimates and

projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,”

“expects,”

“intends,”

“plans,”

“believes,”

“seeks,”

“estimates,”

“may,”

“will,”

and variations of these words or similar

expressions are intended to identify forward-looking statements. These statements include projections about our

future earnings and margins and speak only as of the date hereof. Such statements are based upon the information

available to us now and are subject to change. We will not necessarily inform you of such changes. These statements

are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are

difficult to predict. Therefore our actual results could differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors. The important

factors which could cause actual results to

differ materially from those in the forward-looking statements include, among others, a downturn or leveling

off of

demand for our products due to the availability and pricing of competing products and technologies, adverse

international market or political conditions, a domestic economic recession, the volume and pricing of product sales,

our ability to control costs, intellectual property disputes, the effects of natural disasters and other events beyond our

control and other factors including those detailed in BIOLASE’s filings with the Securities and Exchange Commission

including its prior filings on Form 10-K and 10-Q.

PAGE

2

BIOLASE is Revolutionizing Surgery in Medicine

•

The Er,Cr:YSGG (2780nm) laser crystal has the highest level of absorption in water in human tissue. 

•

This absorption creates an expansion and vaporization of the water molecules causing a biological

ablation of human tissue with very little trauma or bleeding.

•

Tooth enamel ~5% water, dentin and bone ~25% water, soft tissue ~80% water, and the eye ~90% water. 

How?  Through the science of WaterLase!

PAGE 3

Conventional Surgical Devices include the scalpel, high speed drill,

electrosurge, electric bone saws, and heat generating lasers.

…BIOLASE is NOT Just Another Medical Device Company!

BIOLASE

is

the

World

Leader

in

Laser

Dentistry…

…and the Dental Community is the Largest Medical Community in the

World!

PAGE 4

BIOLASE 45%

BIOLASE 45%

Source: iData Research Inc.

2009 US Overall Dental Laser Market: Hard

& Soft Tissue

PAGE 4

BIOLASE 80%

BIOLASE 80%

Source: Biolase Technology Licensing Reports

2009 US Dental Laser Market:

Hard Tissue

Medical:

The

Diolase

10

offers

high

intensity

laser

therapy

in

the palm of your hand for pain management.

Digital Imaging:

equipment, including cone beam 3-D dental imaging and

CAD/CAM digital dental impressions.

Diode

soft-tissue

dental

lasers:

Our

soft

tissue

lasers

include the ezLase total diode solution, which offers power

and portability, and the revolutionary iLase, a portable

diode laser with no foot pedal, power cord, or external

controls.

Current Line of BIOLASE Products

PAGE 5

All-tissue dental lasers:

revolutionary WaterLase iPlus, and the WaterLase MD Turbo.

Our

all-tissue

lasers

include

our

new

flagship

laser,

the

We

offer

a

full

line

of

digital

imaging

Alternative and Advanced Hi-Tech Dentistry

Atraumatic Pediatric Tooth Extraction

The red or green

aiming beam on the

WaterLase does not

cut the tissue or

generate any heat. 

The tissue is cut

biologically, with little

or no pain, by

energizing water at

the molecular level.

Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System:

PAGE 6

The iPlus features an

intuitive, touch-based

computer screen,

similar to a tablet

personal computer. 

It is designed to

allow for remote

servicing and

software upgrades.

WaterLase High Speed Cutting

PAGE 7

In 2011: Single Product Company

1.

Moved from exclusive distribution with

Schein to direct sales and multi-distributor

model.

2.

Launched iPlus which EQUALS the speed of

a traditional dental drill. 

3.

Globalized distribution with approvals in

Canada, Korea, Russia, Taiwan, & others.

4.

Launched digital imaging products.

5.

Growing revenues over 100%.

6.

Continuing to expand global sales footprint.

In 2012: Broaden Platform and Product Portfolio

Becoming a Globally Diversified Platform Company

1.

Diversify revenue base to expand

addressable markets and reduce investor

risk.

2.

Launch 2 to 3 new dental products in

2Q12, including lasers and imaging.

3.

Enter or begin clinical development &

approval in: ophthalmology, orthopedics,

pain management, podiatry, and aesthetics.

4.

Re-launch revised iLase with new

distribution partners.

5.

Reset investor expectations…

,,,under promise, over deliver.

PAGE 8

Why BIOLASE WaterLase Technology in Dentistry?

Traditional high-speed drills

work

by

FRICTION

which

creates

HEAT

which

causes

PAIN. 

This

PAIN

necessitates

injections

of

ANESTHESIA

which

results

in

PAIN

and

NUMB

LIPS.

In addition, the lack of feeling from the numbing injections can

lead to THERMAL DAMAGE

which can lead to PULPAL DEATH and result in a ROOT CANAL.

The traditional high-speed drill

also causes VIBRATION,

which

causes

PAIN

and leads to

MICROFRACTURES.  These MICROFRACTURES allow BACTERIA to penetrate the tooth

which causes further DECAY and the FRACTURING of teeth.

High speed drills

also

require

the

use

of

BURS

which

even

after

autoclaving

have a 15% chance of carrying pathogenic micro-organisms.  Needles

and files

can

also

carry

bacteria.

That

means

in

traditional

dentistry

the

patient

has

a

1

in

6

chance

of

cross

contamination.

WaterLase energy

does not create heat or vibration so there is NO PAIN.  Further, the

WaterLase is bactericidal, antiviral and essentially

eliminates

the

risk

of

cross

contamination.

PAGE 9

Why Dentists Should Buy an iPlus System?

•

WaterLase technology enables traditional dentists to perform procedures that they currently refer out to

specialists or current WaterLase dentists, for example:

•

Gingivectomy = $160

•

Perio Treatment = $375

•

Hard-tissue Crown Lengthening = $520

•

Herpetic or Aphthous Ulcer = $308

•

Frenectomy = $355

•

With no anesthesia, the WaterLase also increases efficiency and allows the dentist to work in multiple

quadrants in a single visit.

•

This equates to $250-$750 per day in additional revenue.  These procedures are easy to learn and training is

included in the cost..

Monthly Lease Payment

New Monthly Revenue

Generated

Approx. $1,000

$5,000 –

$15,000

PAGE 10

A dentists’

return on investment can

be between 500% and 1,500%!

…WaterLase’s Tremendous Return on Investment!

Current Status:

BIOLASE

has

a

tremendous

IP

portfolio

with

284

issued

and

pending

patents,

70%

of

which

are related to our core WaterLase (Er,Cr:YSGG) technology and medical lasers.

Filing

costs

and

maintenance

are

closely

monitored.

Funding

for

redundant

patents

and

patents

with

a

low-

probability for issuance are stopped.

Patent Portfolio

Issued

Pending

Total

U.S.

84

53

137

International

76

71

147

Total

160

124

284

PAGE 11

$50B to $100B WaterLase Market Opportunity

The WaterLase’s global market opportunity is immense…

because the dental community is the largest medical

community in the world.

•

176,000 dentists in the US and Canada.

1

•

Over 1.2 million dentists in 134 countries and growing

rapidly in emerging economies.

2

•

18,000 systems in over 11,000 practices.

•

Every 1% of further market penetration, just with the

WaterLase, is equal to an opportunity of well over $600

million in revenues!

1. American Dental Association.  2. World Federation of Dentistry.  3. 1998-present over 17,300 BIOLASE systems sold.

PAGE 12

Our current market penetration is approximately

3% in the US and slightly less than 1% internationally! 

Estimated total global market of 1,200,000,

which is growing rapidly due to new markets

such as China, India, and Indonesia.

18,000

3

systems sold worldwide.

1. Dental Health Magazine  2. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie

Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA •

www.cda-adc.ca/jcda •

February 2009, Vol. 75, No. 1.  3.

Contaminated dental instruments: Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-5.  4. The

antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting tips on root canal

dentin walls infected with Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron

Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002.   5. The Bacterial

Challenge: Time to React.  A call to narrow the gap between multi-drug resistant bacteria in the EU and the development of

new antibacterial agents., ECDC/EMEA Joint Working Group, Stockholm, Sweden, September, 2009.

Warning:

Patients Urged to Ask their Dentists

About the Risk of Cross Contamination!

Cross contamination is a huge threat:

1,2,3,4

•

The CDC defines cross-contamination as the act

of spreading bacteria and viruses from one surface

to another. Blood-borne viruses have the ability to

live on objects and surfaces for as long as a week.

•

Sterilization techniques used for dental burs used

with

high

speed

drill

and

endodontic

files

are

not

effective.  This is a serious health threat!

•

Many bacteria are becoming more and more

resistant to antibiotics.

5

PAGE 13

The Bacterial Challenge

Antibiotic resistance adversely impacts the health of millions of patients

every year.  Of the patients receiving antibiotics, 50% receive

unnecessary

or

redundant

therapy,

resulting

in

overuse

of

antibiotics.

Resistance to antibiotics is high among bacteria that cause serious

infections in humans and reaches 25% or more in several EU 

Member States.

Each

year,

about

99,000

patients

in

the

US

die

from

hospital

acquired

infections

and 25,000 patients in the EU

die from an infection related

to multidrug-resistant bacteria.

Infections due to these multidrug-resistant bacteria result in extra

healthcare costs and productivity losses of at least EUR 1.5 billion in

the EU each year.

Mortality rates of one resistant strain MRSA in the U.S. exceeded the

combined

death

toll

of

AIDS,

tuberculosis,

and

hepatitis

B.

1. Centers for Disease Control and Prevention. Delivering safe care for patients: all healthcare providers play a role., November 15, 2011.  Source: http://www.cdc.gov/getsmart/healthcare/learn-from-others/factsheets/hc_providers.html.  2. The Bacterial Challenge:

Time to React.  A call to narrow the gap between multi-drug resistant bacteria in the EU and the development of new antibacterial agents., ECDC/EMEA Joint Working Group, Stockholm, Sweden, September, 2009.  3. Klevens RM, Edwards JR, Richards CL, Horan TC. 

Estimating Health-Care Infections and Deaths in US Hospitals, 2002.  Public Helth Reports 2007; 122: 160-166.

1

2

2

2

1

3

WaterLase Tips:

•

Smooth tip surface does not harbor debris or bacteria like

abrasive surface of burs or files.

•

YSGG laser energy is bacteriacidal.

•

Single-use, disposable tips that work without the need to

contact tissue.  Also eliminates accidental sticks with

contaminated burs.

WaterLase MD™

reduced E. faecalis 2.86

times more effectively than NaOCl³

Burs and Endo Files:

•

15% of “sterilized”

burs and up to 76% of “sterilized”

endodontic files carry pathogenic micro-organisms.

•

Complex and rugged bur surface difficult to sterilize.

•

Autoclaving fails 15% of the time to decontaminate burs¹

•Only 32% of endodontic engine-driven files are replaced after

every

case

and

36%

after

every

other

case.

4

BIOLASE is entering a new dental category utilizing WaterLase technology as it

essentially eliminates the risk of cross contamination and contagion:

PAGE 15

Eliminating the Risk of Cross Contamination

1, 2

1. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA • www.cda-adc.ca/jcda • February 2009, Vol. 75, No. 1.  2. Contaminated dental

instruments: Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-5.  3. The antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting tips on root canal dentin

walls infected with Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002

4. Dentaltown Research: Endodontics; Survey, October 2011, dentaltown.com.

3

Patented laser toothbrush for home use:

•

BIOLASE is currently developing a laser toothbrush for consumer home-use in connection with a license

agreement with The Proctor and Gamble Company (“P&G”).

•

Research indicates that a laser toothbrush for home-use will whiten teeth, disinfect teeth and gums, bio-

stimulate

teeth

and

gums,

relieve

pain,

and

perform

photodynamic

therapy.

New lasers:

•

BIOLASE expects to offer additional all-tissue WaterLase products in 2012 that complement the iPlus.

•

Planning to re-launch its handheld diode laser with several new options and applications.

•

Currently engineering more powerful diode soft-tissue lasers for launch in 2012.

New Imaging products:

•

BIOLASE expects to offer additional imaging products in 2012 that complement its current products.

Further Opportunities to Expand in Dentistry

PAGE 16

•

iPlus sales will continue grow rapidly as new products ramp enhancing revenue visibility. 

•

Disposables and consumables will continue to represent ~20% of total sales.

•

New products will expand BIOLASE’s addressable markets 2 to 3 times.

•

BIOLASE

will

re-launch

its

handheld

diode

laser

with

new

distributor

partners

in

early

2012.

2011 (Projected)

2012 (Projected)

WaterLase Systems

~60%

~50%

Diode Systems

~19%

~15%

Consumables &

Other

~20%

~20%

New

~1%

~15%

BIOLASE will diversify in 2012 and expand product sales beyond dentistry.

Diversification in 2012

PAGE 17

With our patented WaterLase and diode technologies, we have created technological

platforms that have the ability to extend far outside of dentistry.

We expect to greatly expand our addressable markets in the coming years which, we

believe, has the potential to  substantially increase our revenues.  Each of these

potential markets represents a multi-billion dollar opportunity.

Ophthalmology:

We

currently

hold

14

issued

and

19

pending

U.S.

and

International

patents

in

four

patent families in the field of ophthalmology, giving us a wide range of applications and coverage.  Our

patented

technology

has

the

capability

to

restore

the

elasticity

of

the

eye

and

allow

it

to

return

to

normal

function, eliminating presbyopia.  Management has established a new subsidiary, OCULASE, which will

own and develop BIOLASE’s ophthalmic assets and technologies.   In 2012, we expect approval to

market

treatments

for

glaucoma

and

dry

eyes.

We

expect

approval

to

market

WaterLase

technology

for

presbyopia internationally in 2013 and in the United States in 2014.

2012: Expanding Beyond Dentistry 

PAGE 18

Aesthetics:

We

have

various

FDA

approvals

for

applications

in

dermatology,

plastic

surgery,

and oculoplastics and are currently investigating options for entering these markets in 2012.

Pain

Management:

We

anticipate

launching

a

new

deep-tissue

hand

piece

and

upgraded

laser

for

pain

therapy in 2012 which will coincide with a new marketing campaign.

Podiatry:

We

have

found

that

our

Diolase

10

technology

is

very

effective

in

the

treatment

of

nail

fungus

and we are completing the clinical and regulatory requirements necessary to enter the market in 2012.

Orthopedics:

We

are

working

with

several

key

manufacturers

and

universities

to

provide

solutions

that

are

not

currently

available.

We

are

investigating

opportunities

for

several

orthopedic

applications

and

anticipate filing several 510(k) applications over the next 12 months.

PAGE 19

2012:

Expanding

Beyond

Dentistry

(Continued)

Quarterly Revenues (in Millions)

PAGE 20

Federico Pignatelli restored

as Chairman & CEO in Aug 2010

Record quarter with

Federico Pignatelli interim

CEO during Q407

2004

2005

2006

2007

2008

2009

2010

2011

Q1-Mar

$    14.5

$    16.8

$    16.9

$    15.1

$    19.0

$      6.6

$      4.4

$    10.6

Q2-Jun

$    14.7

$    14.5

$    15.9

$    18.2

$    18.7

$    14.3

$      5.9

$    12.1

Q3-Sep

$    12.0

$    11.7

$    17.1

$    12.8

$    15.3

$    12.1

$      6.2

$    13.1

Q4-Dec

$    19.1

$    19.0

$    19.8

$    20.8

$    11.6

$    10.4

$      9.7

$-

$5.0

$10.0

$15.0

$20.0

$25.0

Direct sales ramp begins in Sep 2010

Over 100% revenue

growth to date in 2011

compared to 2010

Quarterly Non-GAAP Net Income (in Millions)

2004

2005

2006

2007

2008

2009

2010

2011

Q1-Mar

$   0.783

$ (4.015)

$ (1.462)

$ (0.890)

$  0.985

$ (3.763)

$ (4.797)

$  0.153

Q2-Jun

$   1.006

$ (6.222)

$ (1.340)

$ (0.089)

$  1.578

$  3.020

$ (3.657)

$  0.069

Q3-Sep

$  (0.962)

$ (4.820)

$ (0.167)

$ (2.765)

$ (3.551)

$  1.534

$ (2.173)

$ (0.397)

Q4-Dec

$(23.257)

$ (0.479)

$ (2.466)

$ (0.272)

$ (4.338)

$ (0.888)

$  0.787

Adjustments from net income (loss) include: depreciation and amortization, non-cash stock-based compensation expense, and interest expense.

PAGE 21

$(8.0)

$(6.0)

$(4.0)

$(2.0)

$-

$2.0

$4.0

Federico Pignatelli restored

as Chairman & CEO in Aug 2010

BLTI

Revenues

Chart & Financial History

1994-2006 Pignatelli

Chairman of the Board

Exclusive distribution partnership with

Henry Schein Aug 2006–Aug 2010

Aug 2010-Present

Pignatelli CEO &

Board Chairman

1998  FDA

Clearance

WaterLase

PAGE 22

Volume: Millions of Shares

20

15

10

5

BLTI

Share

Price

BIOLASE Technology, Inc. Today

Company Headquarters in Irvine, California

PAGE 23

•

We have over 180 employees worldwide.

•

We also have manufacturing capabilities in Floss, Germany.

•

We have sales offices in the U.S., Floss (Germany), Madrid

(Spain), Shanghai (China), and Mumbai (India), with expansion

planned in Dubai (UAE), and Rio de Janero (Brazil). We also

have training facilities in Charlotte, NC, and Irvine, CA.

BIOLASE Europe in Floss, Germany

•

Our 57,000 sq. ft. corporate HQ in Irvine houses finance &

administrative, sales, marketing, customer care, training,

manufacturing, and R&D.  This facility can accommodate

growth to $250 million.

•

ISO 9001 certified and FDA GMP with clean room operations.